Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ImmunityBio, Inc. Director's Dealing 2026

Feb 24, 2026

31529_dirs_2026-02-24_49516500-6405-487f-86ef-af108480a2b6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2026-02-20

Reporting Person: Simon Barry J. (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2026-02-20 Common Stock S 10000 $9.25 Disposed 3081604 Direct
2026-02-22 Common Stock M 15243 Acquired 3096847 Direct
2026-02-22 Common Stock F 6026 $8.70 Disposed 3090821 Direct
2026-02-23 Common Stock S 165000 $10.2491 Disposed 2925821 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2026-02-22 Restricted Stock Units $ M 15243 Disposed Common Stock (15243) Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.

F4: Represents the weighted average share price of an aggregate total of 165,000 shares sold in the price range of $9.89 to $10.635 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.